Helen of Troy reported earnings on July 8 with a stock that has rebounded 15% in a month but still carries heavy short interest — and with the borrow market signalling no urgency whatsoever on either side.
The most striking feature of the current setup is the disconnect between short interest and lending conditions. Short interest is genuinely elevated at 11.1% of the free float — about 2.56 million shares, flat to slightly higher on the week — which in isolation reads as meaningful bear conviction. Yet the borrow market tells a completely different story. Availability is running at over 1,300% of shares already borrowed, meaning there are roughly thirteen shares available to lend for every one currently on loan. That is far above the 52-week minimum of 254%, and cost to borrow has eased to around 1.2% after a brief spike last month. The short position is large, but it is not stressed — there is ample room for new shorts and no squeeze pressure in the lending pool. Options add a mild layer of caution: the put/call ratio is at 0.86, about 1.6 standard deviations above its 20-day average of 0.83, nudging toward defensive territory but nowhere near the extremes recorded over the past year (the 52-week high is 1.64). Positioning looks skeptical rather than panicked.
The Street is firmly on the sidelines, and the most recent analyst activity — now roughly 75 days old — reflects that ambivalence. Both UBS and Canaccord raised targets in late April following prior-quarter results, UBS moving from $16 to $25 and Canaccord from $18 to $23, yet both kept neutral or hold ratings. The stock at $28.04 now trades above both those freshly-raised targets, which is worth noting: the consensus mean sits at $29.33, implying minimal upside even at the most optimistic read on the Street. Valuation multiples are cheap in absolute terms — a P/E of 7.4x and price-to-book of 0.72x — but the bear case is structural. The company is navigating roughly a 10% sales decline, with tariff-related order cancellations hitting the direct import channel, softness in beverageware and home categories, and a challenged closeout business. The bull case rests on eight of eleven key brands showing U.S. point-of-sale unit growth, a growing direct-to-consumer arm, and the potential tailwind from a normalised cold and flu season. Factor scores offer little conviction either way: the ORTEX short score is a pedestrian 51.5, EPS surprise ranks in just the 3rd percentile, and the short score rank sits at 20 — none of these signal a high-conviction setup in either direction.
Institutional ownership is worth a quick note. The holder list shows several active managers who built significant new positions in Q1: RWWM added 541,689 shares, Vanguard Capital Management initiated with just over a million shares, AQR added 573,563, and Paradigm built 362,900 shares. These are not passive index flows — they are active managers stepping into a deeply out-of-favour consumer name at distressed valuation levels. BlackRock also nudged its position higher as recently as June 30. That accumulation pattern, taken alongside the cheap multiples, is the clearest institutional signal available.
On the insider side, Acting CEO Brian Grass sold shares in May at $23.93 — above the March lows but well below today's price. He had bought 10,000 shares in July 2025 at $21.47, so the May sales represent a partial trim of a position built at lower levels. The net 90-day insider position is modestly positive at roughly $571,000 in net purchases, though the most recent transactions are sales, not buys.
Closest peers had a rough week: NWL fell 8.6% and MTH dropped 7.1%, while HELE shed 3.5% — a relative outperformance that may partly reflect the earnings catalyst drawing in event-driven positioning. What to watch next is whether July 8 results move the needle enough to bring analyst targets into alignment with the current price, or whether the stock continues to trade above a consensus that has struggled to keep pace with the rebound.
See the live data behind this article on ORTEX.
Open HELE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
